Immunoglobulin Y protects intestinal epithelium and modulates gut microbiota

Abstract

Aim: This study investigated the effects of Muno-IgY®, a multi-pathogen-specific immunoglobulin Y (IgY), on microbial growth, adhesion, fermentation activity, and immune signaling using a multi-tiered in vitro approach.

Methods: IgY activity was first evaluated in Caco-2 adhesion and invasion assays using adherent-invasive Escherichia coli (AIEC) at optimized concentrations, followed by assessment in a SHIME® in vitro gut model inoculated with human fecal microbiota enriched in Enterobacteriaceae. Microbial composition, fermentation markers, and metabolite production were analyzed, and downstream effects on epithelial barrier integrity and immune signaling were evaluated using a Caco-2/peripheral blood mononuclear cell (PBMC) co-culture model exposed to SHIME® effluents.

Results: Muno-IgY® significantly reduced AIEC adhesion/invasion from 39.76% in controls to 13.08% and 9.13% at 3 and 6 mg/mL, respectively (P < 0.05). In the SHIME® model, IgY significantly increased acetate and propionate production (P < 0.05), alongside a marked increase in ammonium concentration (P < 0.01). Microbial biomass increased modestly, while alpha- and beta-diversity indices were not significantly altered. The compositional shifts indicated enrichment of beneficial and mucin-associated taxa and reduction of opportunistic or pathogenic species in the Muno-IgY® group. In Caco-2/PBMC co-cultures, IgY-treated effluent decreased transepithelial electrical resistance (TEER) indicating reduced barrier integrity (P < 0.05) but significantly decreased pro-inflammatory cytokines Interferon-γ (IFN-γ) and Interleukin-22 (IL-22) (P < 0.05).

Conclusions: Muno-IgY® demonstrates the ability to inhibit pathogen adhesion and modulate microbial composition and immune responses in vitro. These findings support its potential as a non-antibiotic approach for microbiome-targeted interventions, although further validation in vivo is required.

Keywords

IgY / gut microbiota / adhesion assay / cytokines / barrier integrity / passive immunotherapy / adherent pathogenic E. coli

References

[1] Fathima S,Shanmugasundaram R,Adams D,Selvaraj RK. Gastrointestinal microbiota and their manipulation for improved growth and performance in chickens Foods. 2022 11 1401 PMC9140538

[2] Shu LZ,Ding YD,Xue QM,Cai W,Deng H. Direct and indirect effects of pathogenic bacteria on the integrity of intestinal barrier Ther Adv Gastroenterol. 2023 16 17562848231176427 PMC10233627

[3] Van Hul M,Cani PD,Petitfils C,De Vos WM,Tilg H,El-Omar EM. What defines a healthy gut microbiome? Gut. 2024;73:1893-908 PMC11503168

[4] Mohsenzadeh A,Pourasgar S,Mohammadi A.et al. The gut microbiota and cardiovascular disease: exploring the role of microbial dysbiosis and metabolites in pathogenesis and therapeutics Life Sci. 2025 381 123981

[5] Kittana H,Gomes-Neto JC,Heck K.et al. Evidence for a causal role for escherichia coli strains identified as adherent-invasive (AIEC) in intestinal inflammation mSphere. 2023 8 e0047822 PMC10117065

[6] Mahdavi AH,Rahmani HR,Nili N,Samie AH,Soleimanian-Zad S,Jahanian R. Effects of dietary egg yolk antibody powder on growth performance, intestinal Escherichia coli colonization, and immunocompetence of challenged broiler chicks Poult Sci. 2010 89 484 94

[7] Shin JH,Yang M,Nam SW.et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection Clin Diagn Lab Immunol. 2002 9 1061 6 PMC120060

[8] Artman C,Idegwu N,Brumfield KD.et al. Feasibility of polyclonal avian Immunoglobulins (IgY) as prophylaxis against human norovirus infection Viruses. 2022 14 2371 PMC9698945

[9] Ibrahim El-SM, Rahman AK, Isoda R, Umeda K, Van Sa N, Kodama Y. In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY) Vaccine. 2008 26 2073 80

[10] Van Nguyen S,Umeda K,Yokoyama H,Tohya Y,Kodama Y. Passive protection of dogs against clinical disease due to Canine parvovirus-2 by specific antibody from chicken egg yolk Can J Vet Res. 2006 70 62 4 PMC1325096

[11] Zhu W,Zhang X,Wang D,Yao Q,Ma GL,Fan X. Simulator of the human intestinal microbial ecosystem (SHIME(®)): current developments, applications, and future prospects Pharmaceuticals (Basel). 2024 17 1639 PMC11677124

[12] Deyaert S,Moens F,Pirovano W.et al. Development of a reproducible small intestinal microbiota model and its integration into the SHIME(®)-system, a dynamic in vitro gut model Front Microbiol. 2022 13 1054061 PMC10063983

[13] De Oliveira FL,Salgaço MK,de Oliveira MT.et al. Exploring the potential of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 as promising psychobiotics using SHIME Nutrients. 2023 15 1521 PMC10056475

[14] Rivera Calo J,Rubinelli PM,Ricke SC. Gentamicin susceptibility and comparison of adhesion and invasion of Caco-2 and HD11 cell lines by Salmonella enterica serotypes Appl Sci. 2024 14 3305

[15] Sivieri K,Morales ML,Adorno MA,Sakamoto IK,Saad SM,Rossi EA. Lactobacillus acidophilus CRL 1014 improved “gut health” in the SHIME reactor BMC Gastroenterol. 2013 13 100 PMC3700768

[16] Sato Y,Kanayama M,Nakajima S,Hishida Y,Watanabe Y. Sialyllactose enhances the short-chain fatty acid production and barrier function of gut epithelial cells via nonbifidogenic modification of the fecal microbiome in human adults Microorganisms. 2024 12 252 PMC10892346

[17] Pieper R,Vahjen W,Zentek J. Intestinal lactose and mineral concentration affect the microbial ecophysiology along the gastrointestinal tract of formula-fed neonatal piglets J Anim Sci. 2016 94 3786 95

[18] Chen H,Wang Z,Zhao Y,Yang W,Huang J,Yu Z. Gut microbial ammonia enhances colonic acetylcholine levels to regulate intestinal motility Nat Microbiol. 2026 11 907 19

[19] Duysburgh C,Verstrepen L,Van Meulebroek L,Marzorati M. Tributyrin (CoreBiome(®)) enhances butyrate levels and modulates the gut microbiota, barrier function, and immune response in vitro Front Nutr. 2025 12 1712993 PMC12746503

[20] Chalghoumi R,Théwis A,Beckers Y,Marcq C,Portetelle D,Schneider YJ. Adhesion and growth inhibitory effect of chicken egg yolk antibody (IgY) on Salmonella enterica serovars Enteritidis and Typhimurium in vitro Foodborne Pathog Dis. 2009 6 593 604

[21] Deng S,Luo X,Du Y.et al. Immunoglobulin Y antibodies against colonization-related genes block the growth and infection of Helicobacter pylori Front Immunol. 2025 16 1582250 PMC12213714

[22] Nilsson E,Amini A,Wretlind B,Larsson A. Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin J Chromatogr B Analyt Technol Biomed Life Sci. 2007 856 75 80

[23] Abbas AT,El-Kafrawy SA,Sohrab SS,Azhar EIA. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections Hum Vaccin Immunother. 2019 15 264 75 PMC6363154

[24] Chen D,Yu J,Wang J.et al. IgY antibodies as a non-antibiotic approach to combat Vibrio vulnificus infection and gut microbiota dysbiosis in zebrafish Fish Shellfish Immunol. 2025 166 110637

[25] Zhao S,Liu W,Wang J.et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice J Mol Endocrinol. 2017 58 1 14

[26] Doi K,Mori K,Komatsu M.et al. Molecular mechanisms of complex-type N-glycan breakdown and metabolism by the human intestinal bacterium Barnesiella intestinihominis J Biosci Bioeng. 2025 139 14 22

[27] Mirsepasi-Lauridsen HC,Vallance BA,Krogfelt KA,Petersen AM. Escherichia coli pathobionts associated with inflammatory bowel disease Clin Microbiol Rev. 2019 32 10.1128/cmr.00060-18 PMC6431131

[28] Li X,Yao Y,Wang X.et al. Chicken egg yolk antibodies (IgY) modulate the intestinal mucosal immune response in a mouse model of Salmonella typhimurium infection Int Immunopharmacol. 2016 36 305 14 PMC7106048

[29] Wang Z,Li J,Li J.et al. Protective effect of chicken egg yolk immunoglobulins (IgY) against enterotoxigenic Escherichia coli K88 adhesion in weaned piglets BMC Vet Res. 2019 15 234 PMC6615277

[30] Ma X,Li M,Zhang Y.et al. Akkermansia muciniphila identified as key strain to alleviate gut barrier injury through Wnt signaling pathway eLife. 2025 12 RP92906 PMC11801796

[31] Liu X,Wang L,Huang B,Jiao Y,Guan Y,Nuli R. Barnesiella intestinihominis improves gut microbiota disruption and intestinal barrier integrity in mice with impaired glucose regulation Front Pharmacol. 2025 16 1635579 PMC12540160

[32] Yan H,Ajuwon KM. Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway PLoS ONE. 2017 12 e0179586 PMC5487041

[33] Mafi M,Rezaei Adriani R,Mohammadkhani F,Mousavi Gargari SL. Development of protective egg yolk immunoglobulins (IgY) targeting CfaB, LTB, and EtpA recombinant proteins of Enterotoxigenic Escherichia coli (ETEC) for inhibiting toxin activity and bacterial adherence Braz J Microbiol. 2025 56 403 13 PMC11885764

[34] Moosavi M,Rahimi S,Torshizi MAK,Salehi TZ,Grimes J. Egg yolk immunoglobulin Y administration on Salmonella Typhimurium colonization, intestinal health, and growth performance in broiler chickens Poult Sci. 2025 104 105487 PMC12275192